<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04642378</url>
  </required_header>
  <id_info>
    <org_study_id>ZSE-202011</org_study_id>
    <nct_id>NCT04642378</nct_id>
  </id_info>
  <brief_title>Study to Assess the Efficacy and Safety of iNCDSS in Type 2 Diabetes Mellitus Patients</brief_title>
  <acronym>iNCDSS-3</acronym>
  <official_title>Study to Assess the Efficacy and Safety of iNCDSS Assisted Insulin Dosage Titration System on Glucose Control in Type 2 Diabetes Mellitus Patients : a Muticenter, Single-blind, Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fifth People's Hospital,Shanghai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xuhui Central Hospital, Shanghai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qingpu Central Hospital,Shanghai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, single-blind, parallel group, randomized controlled trial to access&#xD;
      the effect and safety of the Artificial Intelligence Assisted Insulin Titration System&#xD;
      (iNCDSS) in patients with Type 2 Diabetes Mellitus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As one of the most common treatments for diabetes inpatients, insulin regimens often vary due&#xD;
      to different physicians. Since 2016, Zhongshan Hospital has set up the Internet-based glucose&#xD;
      management system (iGMS) to monitor plasma glucose of diabetes patients, and further set up&#xD;
      an Artificial Intelligence Assisted Insulin Titration System (iNCDSS) to recommend insulin&#xD;
      regime in 2019. Previous single-center clinical trial (NCT04053959) have indicated the&#xD;
      efficacy and safety of iNCDSS in glycemic management in patients with type 2 diabetes.&#xD;
&#xD;
      This multi-center study enrolls 106 patients with Type 2 Diabetes from four sites who are on&#xD;
      treatment with insulin for at least 3 months. They will be randomly allocated into 2 groups&#xD;
      at a ratio of 1:1 after screening for the inclusion and exclusion criteria. Patients in the&#xD;
      Intervention group (iNCDSS group) receive insulin regimen set by iNCDSS and patients in&#xD;
      Regular treatment regime group receive insulin regimen recommended by endocrinologists.&#xD;
&#xD;
      This study will be conducted in the Department of Endocrinology in Shanghai Zhongshan&#xD;
      Hospital, Shanghai fifth People's Hospital, Shanghai Xuhui Central Hospital and Shanghai&#xD;
      Qingpu Central Hospital, and will consist of a 7-day intervention period. Patient allocation&#xD;
      will be stratified by HbA1c, BMI and previous total insulin doses. The primary endpoint is&#xD;
      the time in target glucose range during the 7-day trial period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time in target glucose range</measure>
    <time_frame>During 7-day intervention</time_frame>
    <description>The well-controlled blood glucose level is defined as the time of sensor glucose measurements in targeted range (3.9-10 mmol/L)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of time in which the blood glucose level is over 10 mmol/L</measure>
    <time_frame>During 7-day intervention</time_frame>
    <description>The poor control of blood glucose level is defined as greater than 10 mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of hypoglycemia</measure>
    <time_frame>During 7-day intervention</time_frame>
    <description>The hypoglycemia is defined as blood glucose level less than 3.9mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily insulin dose</measure>
    <time_frame>During 7-day intervention</time_frame>
    <description>The daily insulin dose is defined as daily total insulin dose</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">106</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>iNCDSS group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Artificial intelligence assisted insulin titration system group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Routine treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Physician decided insulin titration group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iNCDSS based insulin regime</intervention_name>
    <description>Patients of this group will receive the insulin regime set by the AI assisted insulin titration system (iNCDSS).</description>
    <arm_group_label>iNCDSS group</arm_group_label>
    <other_name>iGMS + iNCDSS based insulin regime</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>routine insulin treatment regime</intervention_name>
    <description>Patients of this group will receive the insulin regime recommended by professional endocrinologists.</description>
    <arm_group_label>Routine treatment group</arm_group_label>
    <other_name>iGMS + routine insulin treatment regime</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or women aged 18-75 years old;&#xD;
&#xD;
          -  Subjects who had been diagnosed with type 2 diabetes;&#xD;
&#xD;
          -  Subjects who are on treatment with insulin for at least 3 months;&#xD;
&#xD;
          -  HbA1c: 7.0%-11.0%.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with acute complications of diabetes such as ketoacidosis or hyperglycemic&#xD;
             hyperosmolar state;&#xD;
&#xD;
          -  Subjects who change the insulin regimens during hospitalization;&#xD;
&#xD;
          -  BMI â‰¥ 45kg/m2;&#xD;
&#xD;
          -  Women who are pregnant or nursing;&#xD;
&#xD;
          -  Subjects with severe cardiac, hepatic, renal or general diseases;&#xD;
&#xD;
          -  Subjects with psychiatric disorders or impaired cognitive function;&#xD;
&#xD;
          -  Subjects with severe edema, infections or peripheral circulation disorders;&#xD;
&#xD;
          -  Patients treated with surgery during hospitalization;&#xD;
&#xD;
          -  Subjects that are, in the judgement of the investigator, unlikely to comply with the&#xD;
             protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaoying Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Zhongshan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ying Chen, MD</last_name>
    <phone>15351890068</phone>
    <email>baiyuan9873@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>180 Fenglin Road</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Xu Y, Wang L, He J, Bi Y, Li M, Wang T, Wang L, Jiang Y, Dai M, Lu J, Xu M, Li Y, Hu N, Li J, Mi S, Chen CS, Li G, Mu Y, Zhao J, Kong L, Chen J, Lai S, Wang W, Zhao W, Ning G; 2010 China Noncommunicable Disease Surveillance Group. Prevalence and control of diabetes in Chinese adults. JAMA. 2013 Sep 4;310(9):948-59. doi: 10.1001/jama.2013.168118.</citation>
    <PMID>24002281</PMID>
  </reference>
  <reference>
    <citation>Wang T, Xu Y, Xu M, Wang W, Bi Y, Lu J, Dai M, Zhang D, Ding L, Xu B, Sun J, Zhao W, Jiang Y, Wang L, Li Y, Zhang M, Lai S, Wang L, Ning G. Awareness, treatment and control of cardiometabolic disorders in Chinese adults with diabetes: a national representative population study. Cardiovasc Diabetol. 2015 Feb 26;14:28. doi: 10.1186/s12933-015-0191-6.</citation>
    <PMID>25848699</PMID>
  </reference>
  <reference>
    <citation>Ji LN, Lu JM, Guo XH, Yang WY, Weng JP, Jia WP, Zou DJ, Zhou ZG, Yu DM, Liu J, Shan ZY, Yang YZ, Hu RM, Zhu DL, Yang LY, Chen L, Zhao ZG, Li QF, Tian HM, Ji QH, Liu J, Ge JP, Shi LX, Xu YC. Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables. BMC Public Health. 2013 Jun 21;13:602. doi: 10.1186/1471-2458-13-602.</citation>
    <PMID>23800082</PMID>
  </reference>
  <reference>
    <citation>Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R; ATLANTUS Study Group. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care. 2005 Jun;28(6):1282-8.</citation>
    <PMID>15920040</PMID>
  </reference>
  <reference>
    <citation>Oyer DS, Shepherd MD, Coulter FC, Bhargava A, Brett J, Chu PL, Trippe BS; INITIATEplus Study Group. A(1c) control in a primary care setting: self-titrating an insulin analog pre-mix (INITIATEplus trial). Am J Med. 2009 Nov;122(11):1043-9. doi: 10.1016/j.amjmed.2008.12.026.</citation>
    <PMID>19854333</PMID>
  </reference>
  <reference>
    <citation>Yang W, Zhu L, Meng B, Liu Y, Wang W, Ye S, Sun L, Miao H, Guo L, Wang Z, Lv X, Li Q, Ji Q, Zhao W, Yang G. Subject-driven titration of biphasic insulin aspart 30 twice daily is non-inferior to investigator-driven titration in Chinese patients with type 2 diabetes inadequately controlled with premixed human insulin: A randomized, open-label, parallel-group, multicenter trial. J Diabetes Investig. 2016 Jan;7(1):85-93. doi: 10.1111/jdi.12364. Epub 2015 May 25.</citation>
    <PMID>26816605</PMID>
  </reference>
  <reference>
    <citation>Harris S, Yale JF, Dempsey E, Gerstein H. Can family physicians help patients initiate basal insulin therapy successfully?: randomized trial of patient-titrated insulin glargine compared with standard oral therapy: lessons for family practice from the Canadian INSIGHT trial. Can Fam Physician. 2008 Apr;54(4):550-8.</citation>
    <PMID>18411384</PMID>
  </reference>
  <reference>
    <citation>Rigla M, GarcÃ­a-SÃ¡ez G, Pons B, Hernando ME. Artificial Intelligence Methodologies and Their Application to Diabetes. J Diabetes Sci Technol. 2018 Mar;12(2):303-310. doi: 10.1177/1932296817710475. Epub 2017 May 25.</citation>
    <PMID>28539087</PMID>
  </reference>
  <reference>
    <citation>Ashrafzadeh S, Hamdy O. Patient-Driven Diabetes Care of the Future in the Technology Era. Cell Metab. 2019 Mar 5;29(3):564-575. doi: 10.1016/j.cmet.2018.09.005. Epub 2018 Sep 27. Review.</citation>
    <PMID>30269984</PMID>
  </reference>
  <reference>
    <citation>Thabit H, Hartnell S, Allen JM, Lake A, Wilinska ME, Ruan Y, Evans ML, Coll AP, Hovorka R. Closed-loop insulin delivery in inpatients with type 2 diabetes: a randomised, parallel-group trial. Lancet Diabetes Endocrinol. 2017 Feb;5(2):117-124. doi: 10.1016/S2213-8587(16)30280-7. Epub 2016 Nov 9.</citation>
    <PMID>27836235</PMID>
  </reference>
  <reference>
    <citation>Bally L, Thabit H, Hartnell S, Andereggen E, Ruan Y, Wilinska ME, Evans ML, Wertli MM, Coll AP, Stettler C, Hovorka R. Closed-Loop Insulin Delivery for Glycemic Control in Noncritical Care. N Engl J Med. 2018 Aug 9;379(6):547-556. doi: 10.1056/NEJMoa1805233. Epub 2018 Jun 25.</citation>
    <PMID>29940126</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 22, 2020</study_first_submitted>
  <study_first_submitted_qc>November 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2020</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Zhongshan Hospital</investigator_affiliation>
    <investigator_full_name>Xiaoying Li</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>iNCDSS</keyword>
  <keyword>T2D</keyword>
  <keyword>AI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

